74.25MMarket Cap-422P/E (TTM)
10.6812High10.4121Low8.29KVolume10.5200Open10.6100Pre Close87.30KTurnover0.20%Turnover RatioLossP/E (Static)7.04MShares24.400052wk High0.57P/B44.46MFloat Cap10.000052wk Low--Dividend TTM4.21MShs Float382.6000Historical High--Div YieldTTM2.54%Amplitude8.0000Historical Low10.5280Avg Price1Lot Size
Cidara Therapeutics Stock Forum
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenzau
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the first sub...
Dow Jones· 1 min ago
NEWS
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...
Larger Image: tradingview.com...
$Cidara Therapeutics (CDTX.US)$
Hopefully it'll continue to run tomorrow?
WSJ· 4 mins ago
Cidara Therapeutics said it would sell its candidiasis treatment rezafungin to its partner and buy back the license to its potential influenza-prevention treatment.
The San Diego-based biotechnology company said Wednesday that it was divesting the treatment, sold under the brand name Rezzayo, t...
No comment yet